[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Shehab N, Sweet BV, Hogikyan ND: Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy; 2005 Jul;25(7):977-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature.
  • Recurrent respiratory papillomatosis (RRP) is a rare but potentially severe disease caused by papillomavirus, most often types 6 and 11.
  • The disease, which occurs in both juvenile and adult forms, is characterized by benign epithelial tumors of the airway that most frequently affect the larynx but can also spread along the entire aerodigestive tract.
  • Recurrent respiratory papillomatosis is the most common benign neoplasm of the larynx in children and the second most frequent cause of childhood hoarseness.
  • Standard treatment, which is palliative only, consists of surgical excision of papillomata to maintain airway patency and improve voice quality.
  • To date, incorporation of adjuvant treatments has not been reliably beneficial in altering the disease course.
  • To evaluate the data available on the safety and efficacy of cidofovir for the treatment of RRP, we conducted a MEDLINE search for all case reports or series from January 1966-August 2004 describing cidofovir therapy in either adults or children with RRP.
  • Further studies are necessary to determine the most appropriate dose, frequency, and duration of therapy, and to fully characterize the safety profile profile of cidofovir when given intralesionally.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / surgery. Male


2. Patil KK, Ransley PG, McCullagh M, Malone M, Spitz L: Functioning adrenocortical neoplasms in children. BJU Int; 2002 Apr;89(6):562-5
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functioning adrenocortical neoplasms in children.
  • OBJECTIVE: To describe the clinical features, treatment and outcome of functioning adrenocortical tumours in children, and to assess the value of tumour size as a marker for malignant potential.
  • PATIENTS AND METHODS: Twenty-one children (mean age at presentation 4.9 years, range 0.6-11; 12 girls and nine boys) who presented with a functioning adrenal mass over a 29-year period (1972-2000) were assessed.
  • Before 1980 the diagnosis and staging was mainly obtained by intravenous pyelography and plain X-ray.
  • Since 1980, ultrasonography, computed tomography and more recently magnetic resonance imaging were the methods of choice.
  • RESULTS: The mean (range) duration of symptoms before diagnosis was 31 (2-108) months.
  • Three children had malignant neoplasms, one presented with metastasis and of the other two, one died from the disease within 6 months, despite adjuvant chemotherapy and radiotherapy.
  • The third girl is disease-free 11 years after complete excision of the neoplasm.
  • Eighteen children had a benign neoplasm and all are alive and free of recurrence.
  • The virilizing effects of all the neoplasms gradually resolved after surgery within a median (range) of 27 (6-108) months.
  • CONCLUSIONS: Functioning adrenocortical neoplasms in children are rare, with a peak incidence in the first decade, are predominantly unilateral and more common in girls.
  • Most are benign, but both benign and malignant lesions can present with virilizing and Cushingoid features.
  • The malignant neoplasms have an extremely poor prognosis, especially if excision is incomplete, despite adjuvant chemotherapy and radiotherapy.
  • Although there is an association between tumour size and malignancy, this cannot be used as a reliable individual discriminator.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology
  • [MeSH-minor] Child. Child, Preschool. Estrogens / biosynthesis. Female. Humans. Infant. Male. Neoplasm Staging. Organ Size. Testosterone / blood. Treatment Outcome. Virilism / blood. Virilism / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2003 Jul;170(1):322 [14567318.001]
  • (PMID = 11942965.001).
  • [ISSN] 1464-4096
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Estrogens; 3XMK78S47O / Testosterone
  •  go-up   go-down


3. Parreira LM, Sípoli JM, Mercante AM, Orfali RL, Levites J: Case for diagnosis: (unilateral multiple piloleiomyoma). An Bras Dermatol; 2009 Mar-Apr;84(2):197-9
Hazardous Substances Data Bank. HYDROXYZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case for diagnosis: (unilateral multiple piloleiomyoma).
  • Piloleiomyoma is a benign neoplasm arising from the erector pilorum muscle in the skin.
  • [MeSH-major] Leiomyomatosis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antipruritics / administration & dosage. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Female. Humans. Hydroxyzine / administration & dosage. Muscle, Smooth / pathology. Pain / diagnosis. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19503991.001).
  • [ISSN] 1806-4841
  • [Journal-full-title] Anais brasileiros de dermatologia
  • [ISO-abbreviation] An Bras Dermatol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antipruritics; 30S50YM8OG / Hydroxyzine
  •  go-up   go-down


Advertisement
4. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • MPM has a limited response to conventional chemotherapy and radiotherapy so diagnosing MPM early is very important.
  • Here, we investigated the serum levels of VEGF in patients with MPM in comparison with a population that had been exposed to asbestos without developing MPM.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • RESULTS: We demonstrated that patients with MPM had significantly higher serum levels of VEGF than a population who had been exposed to asbestos but had not developed MPM, and the patients with advanced stage MPM showed higher levels of VEGF than the early stage patients with MPM.
  • CONCLUSIONS: Our data suggest that the VEGF serum concentration could be a useful marker for screening MPM among asbestos-exposed individuals and as a prognostic factor.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


5. Alebouyeh M, Moussavi F, Tabari AK, Vossough P: Aggressive intra-abdominal fibromatosis in children and response to chemotherapy. Pediatr Hematol Oncol; 2005 Sep;22(6):447-51
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive intra-abdominal fibromatosis in children and response to chemotherapy.
  • Intra-abdominal fibromatosis (IAF) is a rare benign neoplasm arising from the abdominal fibrous tissue, mostly in the mesentery.
  • The authors report on a boy who presented with a large IAF at the age of 5 years.
  • Within 6 months after initial presentation, he underwent 4 subsequent abdominal explorations for diagnosis, tumor reduction, and intestinal obstructions.
  • Due to accelerated tumor growth and deteriorated general condition, as a last resort, a chemotherapy trial with vincristin and methotrexate was carried out.
  • This regimen proved to be effective in reducing the tumor burden and improving the patient's general condition.
  • Outcome of IAF depends on early diagnosis and complete tumor resection, and, if indicated, timely employment of neo/adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fibromatosis, Abdominal / drug therapy. Fibromatosis, Aggressive / drug therapy
  • [MeSH-minor] Child, Preschool. Humans. Male. Methotrexate / administration & dosage. Tumor Burden / drug effects. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Aggressive Fibromatosis.
  • Genetic Alliance. consumer health - Fibromatosis.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169811.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Patel Y, Mitchell CD, Hitchcock RJ: Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology; 2003 Jun;61(6):1260
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases.
  • Congenital mesoblastic nephroma was originally considered to be a benign neoplasm.
  • We describe a patient with isolated metastasis to liver and review the management, together with evidence that it may be more appropriate to use a vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) regimen rather than Wilm's tumor-based regimens in those cases for which chemotherapy is indicated.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Kidney Neoplasms / congenital. Kidney Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Liver Neoplasms / secretion. Nephroma, Mesoblastic / drug therapy. Nephroma, Mesoblastic / secondary. Sarcoma / drug therapy


7. Karnak I, Senocak ME, Ciftci AO, Cağlar M, Bingöl-Koloğlu M, Tanyel FC, Büyükpamukçu N: Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg; 2001 Jun;36(6):908-12
Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: diagnosis and treatment.
  • BACKGROUND/PURPOSE: Inflammatory myofibroblastic tumor (IMT) is a rare benign neoplasm.
  • Herein, the authors present their experience with IMT with special emphasis on diagnosis and treatment.
  • METHODS: All records of children treated with diagnosis of IMT between 1977 and 1999 inclusive were evaluated retrospectively.
  • Respiratory symptoms and clubbing were present in a patient with pulmonary IMT (n = 1).
  • Tumor sizes ranged from 3 x 2 x 2 cm to 15 x 15 x 13 cm.
  • Total surgical excision of IMT was considered adequate for treatment in 6 cases.
  • One patient with aggressive IMT required further treatments such as immunomodulation and chemotherapy and died of neutropenic sepsis.
  • CONCLUSIONS: IMT is a benign neoplasm rarely presented with malignant features such as local invasiveness, recurrence, distant metastasis, or malignant transformation.
  • IMT can be suspected preoperatively through some hematologic abnormalities and radiologic findings, but precise diagnosis should be made on the basis of histologic findings.
  • Complete surgical resection and close follow-up are all necessary for appropriate treatment to avoid recurrences as well as unnecessary and potentially harmful therapy.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / surgery
  • [MeSH-minor] Child. Female. Humans. Male. Recurrence. Retrospective Studies. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11381424.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


8. Kimberlin DW: Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res; 2004 Sep;63(3):141-51
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis.
  • HPV infections of the genital tract are of medical and public health concern due to their propensity to lead to the development of cervical cancer, and because they can be transmitted to the respiratory tract of a newborn child, resulting in juvenile-onset recurrent respiratory papillomatosis (JO-RRP).
  • JO-RRP is the second most common cause of hoarseness among pediatric patients, and is the most common benign neoplasm in the larynx.
  • The traditional treatment for JO-RRP is the physical removal of the wart through laryngoscopy and surgical debulking of the airway papillomas.
  • In a minority of patients, surgical management must be supplemented with adjuvant medical therapy, with interferon being the best studied and most commonly utilized.
  • Recently, a Phase II investigation of a therapeutic vaccine yielded promising results, and a Phase III evaluation of this therapeutic modality is planned.
  • Other adjuvant treatments currently being utilized, but for which controlled data of benefit are lacking, include cidofovir, indole-3-carbinol, ribavirin, mumps vaccine, and photodynamic therapy.
  • As with surgical management, viral persistence occurs following treatment with these adjuvant modalities, further contributing to the challenge of managing patients with this potentially devastating disease.
  • [MeSH-major] Antiviral Agents / therapeutic use. Papillomaviridae. Papillomavirus Infections / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15451182.001).
  • [ISSN] 0166-3542
  • [Journal-full-title] Antiviral research
  • [ISO-abbreviation] Antiviral Res.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / N01-AI-15113; United States / NIAID NIH HHS / AI / N01-AI62554; United States / NCRR NIH HHS / RR / RR-032
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 103
  •  go-up   go-down


9. Billmire D, Vinocur C, Rescorla F, Colombani P, Cushing B, Hawkins E, London WB, Giller R, Lauer S: Malignant mediastinal germ cell tumors: an intergroup study. J Pediatr Surg; 2001 Jan;36(1):18-24
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This review was conducted to determine clinical characteristics and response to therapy in this rare pediatric neoplasm.
  • METHODS: An intergroup Pediatric Oncology Group (POG) 9049/Children's Cancer Study Group (CCG) 8882 randomized trial was conducted to evaluate response rate and survival with chemotherapy using etoposide, bleomycin, and high or standard dose cisplatin for high-risk malignant germ cell tumors at extragonadal sites.
  • Younger patients had respiratory complaints; older patients had chest pain, precocious puberty, or facial fullness.
  • Yolk sac tumor was the only malignant element in girls.
  • Boys had yolk sac tumor in 7, germinoma in 3, choriocarcinoma in 2, and mixed malignant elements in 15.
  • Benign teratoma elements coexisted in 22 patients.
  • Four patients had biopsy and chemotherapy without tumor resection, and only 1 survived.
  • Fourteen patients had resection at diagnosis followed by chemotherapy with 12 survivors.
  • Eighteen patients had biopsy followed by chemotherapy and postchemotherapy tumor resection with 13 survivors.
  • Tumor size in response to chemotherapy for these 18 patients was stable or increased in 6, and decreased in 12 (mean decrease of 57% in greatest dimension).
  • Overall, 26 of 36 patients survived, with a 4-year patient survival rate of 71%+/-10%, and a 4-year event-free survival rate of 69%+/-10%.
  • Ten patients died: 5 of tumor (all boys > or =15 yr), 2 of sepsis, and 3 of second malignancy.
  • CONCLUSIONS: Malignant MGCT is a complex tumor of varied histology with frequent coexistence of benign elements.
  • Lesions often have incomplete regression with chemotherapy alone.
  • Tumor resection may be undertaken at diagnosis or after attempted shrinkage with chemotherapy.
  • Aggressive attempt at complete tumor resection should be offered to all patients even if bulky tumor persists after induction chemotherapy with expectation of a significant salvage rate.
  • Boys > or =15 years may be a high-risk subgroup for mortality from tumor progression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mediastinal Neoplasms / drug therapy. Neoplasms, Germ Cell and Embryonal / drug therapy
  • [MeSH-minor] Adolescent. Biopsy. Bleomycin / administration & dosage. Child. Child, Preschool. Cisplatin / administration & dosage. Disease-Free Survival. Etoposide / administration & dosage. Female. Humans. Infant, Newborn. Male. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11150432.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Wang JH, Zhang SC, Liu ZD, Chen XY, Li CY, Han Y, Ma Y: [Correlation between the mRNA levels of carcinoembryonic antigen and cytokeratin 19 in peripheral blood with staging, treatment response and prognosis in patients with lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2005 Nov;28(11):773-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between the mRNA levels of carcinoembryonic antigen and cytokeratin 19 in peripheral blood with staging, treatment response and prognosis in patients with lung cancer].
  • OBJECTIVE: To investigate the expression of carcinoembryonic antigen (CEA) and cytokeratin19 (CK19) mRNAs in peripheral blood of patients with lung cancer and their correlation with staging, treatment response and prognosis.
  • METHODS: CEA and CK19 mRNAs in peripheral blood were detected by Taq Man reverse transcriptase-polymerase chain reaction (RT-PCR) in 78 patients with lung cancer before and after treatment, 30 patients with benign lung diseases and 30 healthy subjects.
  • Serum CEA and CYFRA21-1 levels were also measured by enzyme linked immunosorbent assay (ELISA) in the 78 patients with lung cancer before treatment.
  • RESULTS: The positive rates of CEA mRNA and CK19 mRNA in patients with lung cancer were 69.2% (54/78) and 62.8% (49/78), respectively, which were significantly higher than those in patients with benign lung diseases and the healthy controls (P < 0.01).
  • The positive rates of CEA mRNA and CK19 mRNA decreased significantly after surgical operation, but there was no significant change after chemotherapy.
  • The median survival time (MST) for patients with a positive CEA mRNA before chemotherapy was shorter than those with a negative CEA mRNA (8.5 month and 11.7 month, respectively).
  • The MST for patients with a positive CK19 mRNA before chemotherapy was shorter than those with a negative CK19 mRNA (8.9 month and 12.3 month, respectively).
  • The rate of relapse and metastasis was higher in patients (29.4%) with a positive CEA mRNA preoperatively than those with a negative CEA mRNA (7.7%).
  • The rate of relapse and metastasis was also higher in patients with a positive CK19 mRNA preoperatively (18.8%) as compared to those with a negative PCR result (7.1%).
  • CONCLUSIONS: CEA and CK19 mRNAs can be used as markers in the detection of tumor micrometastases in lung cancer, and in evaluating surgical response and prognosis.
  • The results suggest that the gene markers are better than the serum ones, and therefore may be useful for the early diagnosis of lung cancer.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Keratin-19 / blood. Lung Neoplasms / blood. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16324274.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


11. Chen M, Liu J, Yu W, Lu B, Dai Y: [Relation between the serum tissue polypeptide specific antigen level and the biological demeanour of lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2002 May;25(5):262-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relation between the serum tissue polypeptide specific antigen level and the biological demeanour of lung cancer].
  • OBJECTIVE: To investigate the relation between the serum tissue polypeptide specific antigen and the biological demeanour of lung cancer and analyze its clinical meaning for diagnosis of lung cancer.
  • RESULTS: The serum TPS in patients with lung cancer (273 +/- 172) U/L was significantly higher than the with benign lesions [(115 +/- 97) U/L, P < 0.001].
  • 16 post-chemotherapy patients show a lower TPS [(178 +/- 80) U/L] than pre-chemotherapy [(252 +/- 166) U/L, P < 0.05].
  • CONCLUSION: Serum TPS level is closely connected with TNM stages, histological grades and lymphoid node metastases and may serve as a novel marker for diagnosis of lung cancer.
  • [MeSH-major] Lung Neoplasms / pathology. Tissue Polypeptide Antigen / blood
  • [MeSH-minor] Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12133315.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tissue Polypeptide Antigen
  •  go-up   go-down


12. Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A, Kazimierczak K, Klinger M: Kaposi's sarcoma in renal transplant recipients. Ann Transplant; 2005;10(2):59-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a spindle-shaped vascular cell tumor that occurs in the skin, lymphoid, respiratory and gastrointestinal tissues.
  • It may resemble aggressive malignant neoplasm in HIV-related or in post-transplant types but classic form may behave as benign, potentially controllable and reversible hyperplasia.
  • KS occurrence is associated with: type and dose of immunosuppression, chronic stimulation by foreign allograft antigens, viral infections (Herpes virus 8), anti rejection and induction therapy, etc.
  • There is no uniform schema of KS treatment in renal transplant recipients.
  • After conversion to MMF regression of KS was observed, although low therapeutic MMF doses seem to be appropriate.
  • Sirolimus seems to inhibit the growth of established vascularized tumors and this effect is best realized with relatively low immunosuppressive doses of drug.

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16218035.001).
  • [ISSN] 1425-9524
  • [Journal-full-title] Annals of transplantation
  • [ISO-abbreviation] Ann. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 25
  •  go-up   go-down


13. Kawamura S, Nakamura T, Oya T, Ishizawa S, Sakai Y, Tanaka T, Saito S, Fukuoka J: Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy. Pathol Int; 2007 Apr;57(4):213-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced malignant solitary fibrous tumor in pelvis responding to radiation therapy.
  • Solitary fibrous tumor (SFT) is a rare spindle cell neoplasm that is benign in most cases.
  • Herein is reported a case of a 74-year-old woman with a giant malignant SFT in the pelvis.
  • Along with massive invasion to adjacent organs and multiple lung metastases detected on radiography, biopsy from the tumor through the vaginal wall showed malignant looking spindle-cell neoplasm with increased cellularity, areas of necrosis, and high mitotic activity (5/10 high-power fields).
  • Immunohistochemically, the tumor cells were diffusely and strongly positive for CD34, CD99, and bcl-2.
  • Based on pathological features and clinical presentation, diagnosis of malignant SFT was made.
  • The patient received systemic and the intra-arterial chemotherapy followed by whole pelvic radiation therapy (50 Gy).
  • Initial chemotherapies failed to control the tumor.
  • Afterwards, improvement was observed radiologically and pathologically in the 12 months' follow up after the radiation therapy.
  • This is the first report related to therapeutic remarks on advanced malignant SFT.
  • [MeSH-major] Carcinoma / radiotherapy. Neoplasms, Fibrous Tissue / radiotherapy. Pelvic Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Disease Progression. Female. Humans. Magnetic Resonance Imaging. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17316417.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


14. Kukkady A, Upadhyay V, Pease PW, Chan YF: Pleuropulmonary blastoma: four cases. Pediatr Surg Int; 2000;16(8):595-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleuropulmonary blastoma (PPB) is a rare malignant neoplasm affecting children.
  • The presentation, diagnosis, treatment, and family history were studied.
  • PPB usually presents with symptoms and signs of respiratory tract infection, and the diagnosis may be delayed.
  • The diagnosis is made on histologic examination of tumour material and is sometimes difficult to differentiate from benign cystic lung lesions.
  • The treatment is primarily complete excision of the tumour, followed in some cases by intense chemotherapy.
  • Four patients treated at our institute are discussed along with a review of the literature.
  • [MeSH-major] Lung Neoplasms / diagnosis. Neoplasms, Multiple Primary / diagnosis. Pleural Neoplasms / diagnosis. Pulmonary Blastoma / diagnosis

  • Genetic Alliance. consumer health - Pleuropulmonary blastoma.
  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11149404.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Gupta HT, Robinson RA, Murray RC, Karnell LH, Smith RJ, Hoffman HT: Degrees of dysplasia and the use of cidofovir in patients with recurrent respiratory papillomatosis. Laryngoscope; 2010 Apr;120(4):698-702
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Degrees of dysplasia and the use of cidofovir in patients with recurrent respiratory papillomatosis.
  • OBJECTIVES/HYPOTHESIS: Recurrent respiratory papillomatosis (RRP) is a benign disease characterized by recurrent lesions in the airway.
  • Adjuvant therapies, such as cidofovir, have been tried with the goal of decreasing the interval between repeat surgical treatments, the mainstay of therapy.
  • Pathologic data collected over 10 years from serial excisions at the University of Iowa Hospitals were reviewed by a single pathologist, and the highest degree of dysplasia was noted per excision time.
  • A comparison of each patient's multiple biopsies across time suggested that the dysplastic grade was worse in two patients, better in four patients, and virtually unchanged in seven patients.
  • There was no clear-cut pattern between the use of cidofovir and the degree of dysplasia over time.
  • CONCLUSIONS: These results strongly suggest that intralesional cidofovir therapy does not correlate with worsening dysplastic progression.
  • [MeSH-major] Cytosine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / therapeutic use. Respiratory Mucosa / pathology. Respiratory Tract Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Papilloma. Retrospective Studies. Severity of Illness Index. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205173.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


16. Bubendorf L, Savic S: [Predictive EGFR gene analyses in cytology]. Pathologe; 2009 Dec;30 Suppl 2:136-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The isolation or selection of a pure tumour cell population is critical for mutation analysis by PCR and sequencing in order to avoid an admixture of tumour DNA with normal DNA of adjacent benign cells.
  • The collection of tumour cells is easily possible by laser microdissection (LMD).EGFR FISH analysis on cytological specimens with a high proportion of benign respiratory cells should be performed after automated relocation of carcinoma cells.
  • The only hitherto established EGFR-FISH criteria were developed using histological specimens and cannot be applied to cytological specimens as such.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Genetic Markers / genetics. Lung Neoplasms / genetics. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Antineoplastic Agents / therapeutic use. Biopsy, Fine-Needle. DNA Mutational Analysis. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. False Positive Reactions. Humans. In Situ Hybridization, Fluorescence. Lung / pathology. Microdissection / instrumentation. Polymerase Chain Reaction. Predictive Value of Tests. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Br J Cancer. 2008 Jan 15;98(1):154-60 [18087280.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):587-95 [17290067.001]
  • [Cites] Pathologe. 2009 Sep;30(5):384-92 [19357847.001]
  • [Cites] Lung Cancer. 2010 May;68(2):192-7 [19616866.001]
  • [Cites] Science. 2007 May 18;316(5827):1039-43 [17463250.001]
  • [Cites] Lung Cancer. 2009 Mar;63(3):315-21 [18760859.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):983-94 [18281673.001]
  • [Cites] Clin Cancer Res. 2006 Dec 15;12(24):7232-41 [17189394.001]
  • (PMID = 19859710.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 0 / Genetic Markers; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


17. Xu AH, Yin YW, Chen FH: [The value of serum endostatin level in early diagnosis of lung cancer]. Zhonghua Yi Xue Za Zhi; 2006 Jul 18;86(27):1916-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of serum endostatin level in early diagnosis of lung cancer].
  • OBJECTIVE: To investigate value of serum endostatin level in early diagnosis of lung cancer.
  • The serum endostatin levels of the lung cancer patients at different clinical stage and of different pathological types were analyzed.
  • The change of serum endostatin level before and after chemotherapy was observed.
  • Twenty patients with benign lung disease and 20 normal persons were used as controls. RESULTS:.
  • (1) The serum endostatin level of the lung cancer patients was 10.71 +/- 9.99) ng/ml, significantly higher than those of the patients with benign lung diseases and the normal persons (4.79 +/- 1.23 ng/ml and 4.51 +/- 1.14 ng/ml, respectively, both P < 0.01). (2) The serum endostatin level of the lung cancer patients at the stage I and II were 13.63 +/- 13.13 ng/ml and 12.35 +/- 5.79 ng/ml respectively, booth significantly higher than that of the patients at the stage III (6.29 +/- 1.64, P = 0.023 and P = 0.023). (3) There were no significant differences in the serum endostatin level among the lung cancer patients with different pathological types. (4) The serum endostatin level of the lung cancer patients after chemotherapy was 7.83 +/- 1.48 ng/ml, significantly higher than that before the chemotherapy (5.59 +/- 1.74, P = 0.04).
  • CONCLUSION:. (1) Rising in lung cancer at stages I and II, level of serum may probably be used as the a sign in early diagnosis of lung cancer. (2) After chemotherapy the level of endostatin has a trend of rising.
  • The changes of serum endostatin level will be used as a sign in observation of treatment and prognosis.
  • [MeSH-major] Endostatins / blood. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Aged. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Serologic Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17064531.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Endostatins
  •  go-up   go-down


18. Szyfter W, Wierzbicka M, Jackowska J, Bartochowska A, Banaszewski J: [The schedule of intralesional papillomatosis treatment with cidofovir]. Otolaryngol Pol; 2010 Mar-Apr;64(2):98-102
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The schedule of intralesional papillomatosis treatment with cidofovir].
  • INTRODUCTION: Recurrent respiratory papillomatosis (RRP) is a rare disease in children and adults.
  • It is characterized by proliferation of benign squamous cell papillomas within the respiratory-digestive tract, predominantly the larynx.
  • Standard treatment consists of surgical excision of papillomata to maintain airway patency and voice quality.
  • For last several years cidofovir is the most contemporary adjuvant anti-viral treatment for recurrent respiratory papillomatosis and its topical use is widely described.
  • MATERIAL AND METHODS: Intralesional cidofovir therapy was given to 20 patients treated for laryngeal papillomas in the Department of Otolaryngology in Poznan between I-XII.2009.
  • The number of cidofovir injections per patient varied from one to six times and the volume of solution ranges from 1-12 ml.
  • CONCLUSIONS: Intralesional cidofovir injection has been shown to be an effective an safe therapy for laryngeal papilloma and should be considered in those patients who experienced disease relapse.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Combined Modality Therapy. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Poland. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568538.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


19. Lee YC, Lee JW: Innovative treatment for huge nuchal desmoid tumour: a case report with a 2-year follow-up. J Plast Reconstr Aesthet Surg; 2010 Aug;63(8):e622-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Innovative treatment for huge nuchal desmoid tumour: a case report with a 2-year follow-up.
  • BACKGROUND: The desmoid tumour is a monoclonal neoplasm originating from musculoaponeurotic tissues.
  • It is benign in histological presentations and yet its locally invasive behaviour could lead to dire consequences such as disfigurement, functional impairment or even mortality.
  • Surgical resection, radiotherapy, chemotherapy, hormonal therapy, non-steroidal anti-inflammatory drugs and even a wait-and-see policy, either alone or in combination, were advocated as treatment modalities.
  • METHODS: In an effort to prevent uncontrollable tumour bleeding, we embarked on a series of strategic measures, including pre-surgical embolisation, innovative tourniquet technique, a novel method of ligature deployment, staged tumour excision and adjunct methods, such as ethanol injection and irradiation therapy.
  • The patient went through a number of complications such as sepsis, acute respiratory distress and renal failure.
  • [MeSH-major] Embolization, Therapeutic / methods. Fibromatosis, Aggressive / therapy. Head and Neck Neoplasms / therapy. Suture Techniques / instrumentation. Tourniquets
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Neck Dissection / methods. Time Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20304713.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Schwab R, Schneider C, Junge K, Stumpf M, Becker HP, Schumpelick V: [Large solitary fibrous tumors of the pleura as incidental finding. 2 case reports of a rare tumor entity]. Chirurg; 2004 Feb;75(2):200-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Large solitary fibrous tumors of the pleura as incidental finding. 2 case reports of a rare tumor entity].
  • The solitary fibrous tumor (SFT) is a very rare and usually benign neoplasm.
  • This tumor is mostly located in the thoracic cavity, but it has also been reported in numerous sites including liver, skin, and meninges.
  • Due to its rarity diagnosis is often difficult.
  • The treatment of choice for solitary fibrous tumors is extensive surgical resection.
  • Up to now there is no evidence that radiation and chemotherapy are effective.
  • In cases of benign classification (60-80%), the recurrence rate was only 2% after surgical excision.
  • We report two cases of a 65- and a 75-year-old male patient with huge intrathoracic solitary fibrous subpleural tumors, discovered incidentally on routine chest X-ray.
  • [MeSH-major] Incidental Findings. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / surgery
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Humans. Male. Pleura / pathology. Pleura / surgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cardiovasc Surg (Torino). 2002 Aug;43(4):559-61 [12124574.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Oct;259(9):470-3 [12386749.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):213-9 [10380040.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12 ):1501-11 [9850176.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Mar;75(3):363-72 [633933.001]
  • [Cites] J Pathol. 1997 Apr;181(4):362-7 [9196431.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Feb;19(2):185-9 [11167110.001]
  • [Cites] Chirurg. 1999 Aug;70(8):949-52 [10460294.001]
  • [Cites] Pathol Int. 1998 Jan;48(1):47-52 [9589464.001]
  • [Cites] Thorax. 1991 Dec;46(12):930-1 [1792643.001]
  • [Cites] Am J Clin Pathol. 1996 Aug;106(2):217-24 [8712177.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):521-5 [11201008.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):63-8 [10665915.001]
  • [Cites] Cancer. 1979 Oct;44(4):1465-75 [498021.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1841-7 [10362810.001]
  • (PMID = 14991184.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


21. Jurcić V, Perković T, Pohar-Marinsek Z, Hvala A, Lazar I: Infantile myofibroma in a prematurely born twin: a case report. Pediatr Dermatol; 2003 Jul-Aug;20(4):345-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infantile myofibromatosis is a rare benign tumor of infancy and childhood that occurs in solitary, multiple, and generalized forms with similar histology but different clinicopathologic and prognostic implications.
  • Even solitary tumors need follow-up, as the type of presentation will be determined over time.
  • It is necessary to differentiate this entity from other more aggressive tumors, especially rhabdomyosarcoma, which is treated by chemotherapy prior to excision.
  • We describe a prematurely born twin girl who had at birth a solitary tumor of the cervicoscapular region, involving the dermis and subcutis.
  • A fine-needle aspiration biopsy (FNAB) specimen obtained soon after her birth suggested a diagnosis of benign neoplasm.
  • The tumor was excised 1 month later, at which time it was significantly enlarged, ulcerated, and also exhibited worrisome histologic features including mitoses and infiltrative growth.
  • It had the characteristic histologic pattern of infantile myofibromatosis, and myofibroblastic features of tumor cells were confirmed immunohistochemically and ultrastructurally.
  • [MeSH-major] Diseases in Twins. Infant, Premature, Diseases / pathology. Leiomyoma / congenital. Leiomyoma / pathology. Skin Neoplasms / congenital. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Premature Babies.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12869160.001).
  • [ISSN] 0736-8046
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yung RC: Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy. Respir Care Clin N Am; 2003 Mar;9(1):51-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue diagnosis of suspected lung cancer: selecting between bronchoscopy, transthoracic needle aspiration, and resectional biopsy.
  • In pursuing a tissue diagnosis of a suspected lung cancer, there is a range of procedures to choose from.
  • The principal goals are ideally to diagnose and pathologically stage the patient's lung cancer at the same time, preferably by using the safest, least invasive, and least costly tests.
  • If there is clinical or radiographic evidence of extrapulmonary spread of disease, including supraclavicular N3 nodal involvement or a malignant pleural effusion, then radiology-guided or open biopsy will confirm tumor cell type and stage the patient as unresectable.
  • For patients with symptoms, such as increasing cough or hemoptysis, that are suggestive of airways involvement. with or without radiographic finding of central lesions, sputum cytology is the least invasive study with a high specificity.
  • Bronchoscopy with direct examination of the visible airways is most often the preferred invasive diagnostic procedure.
  • Although the procedure should be geared toward sampling the highest staged lesion to provide an accurate tissue staging at the time of diagnosis, additional procedures can be performed in sequence to sample different nodal stations, is well as the primary lung mass.
  • The incidental finding of an unexpected central airways lesions or a synchronous second endobronchial lung primary will also affect plans for treatment.
  • Autofluorescence bronchoscopy can improve the sensitivity for detecting early intraepithelial neoplasia.
  • For visible endobronchial lesions, given the similar yield of EBBX and EBNA, EBNA may provide an immediate diagnosis, thus obviating additional, possibly morbid, procedures such as BB or EBBX.
  • Under all circumstances, immediate cytology feedback with ROSE will confirm the adequacy of the retrieved specimen for a definitive tissue diagnosis, thus avoiding the need for extra biopsies, or worse yet, the need for a second invasive procedure because of insufficient diagnostic material.
  • The diagnostic sensitivity of TTNA is high, especially for the larger peripheral-based lung lesion, and TTNA is a relatively rapid procedure.
  • TTNA may then provide the tissue diagnosis to permit initiation of cytotoxic chemotherapy and radiotherapy.
  • TTNA may also be helpful in cases where the likelihood of cancer is only intermediate, such that a specific benign diagnosis or an adequate sample without cancer will greatly reduce the likelihood ratio of missing a cancer, and justify to the patient and physician an approach of careful observation.
  • Definitive curative surgery remains the goal for patients with lung cancer, with accurate pathological staging performed intraoperatively.
  • Therefore, for patients with sufficient cardiopulmonary reserve who can be clinically staged as IA or IB, either by good quality CT with contrast or increasingly with 18-FDG PET, the initial tissue diagnosis may be at the time of surgery, when a frozen section preceding a complete lobectomy with lymph node sampling will combine diagnosis and therapy.
  • [MeSH-major] Biopsy, Needle / methods. Bronchoscopy / methods. Cytodiagnosis. Lung Neoplasms / diagnosis. Mediastinal Neoplasms / diagnosis. Thoracic Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820712.001).
  • [ISSN] 1078-5337
  • [Journal-full-title] Respiratory care clinics of North America
  • [ISO-abbreviation] Respir Care Clin N Am
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58184
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 159
  •  go-up   go-down


23. Bielecki I, Mniszek J, Cofała M: Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children. Int J Pediatr Otorhinolaryngol; 2009 May;73(5):681-4
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children.
  • In children, the disease produces benign lesions, which grow rapidly and show a marked tendency to recur once removed.
  • There is currently no effective therapy for recurrent respiratory papillomatosis (RRP).
  • The basic goal of treatment is to preserve the patency of air passages while simultaneously preserving the phonatory and anatomical functioning of the larynx.
  • Over the last 10 years, the possibility of a pharmacological treatment has been continually explored: in particular, the administration of locally passed cidofovir (first reported in a 1999 study by Pransky) to the larynx with papillomas is under current scrutiny.
  • GOAL OF STUDY: The goal of the following study is to estimate the effectiveness of locally administered cidofovir for treatment of papillomas of the larynx in children.
  • RESULTS: Seven of the 10 patients achieved total remission 6 months after the completion of treatment, scoring 0 points on Derkay's scale.
  • These patients underwent therapy with cidofovir from 6 to 13 months.
  • Three months after the completion of treatment, three children suffered a recurrence of papillomas.
  • CONCLUSIONS: The results of the study indicate that intralesional injections of cidofovir can be an effective method of treatment for recurrent respiratory papillomatosis in children.
  • [MeSH-major] Antiviral Agents / therapeutic use. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / therapeutic use. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Injections, Intramuscular. Laryngeal Muscles. Male. Neoplasm Recurrence, Local. Neoplasm Staging. Remission Induction

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19193450.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


24. Lesinski-Schiedat A, Hemmanouil I, Sauer-Gönen M, Flemming P, Freihorst I, Kempf HG, Lenarz T: [Malignant transformation of a juvenile papilloma in a 11 year old boy]. Laryngorhinootologie; 2005 Aug;84(8):602-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of a juvenile papilloma in a 11 year old boy].
  • BACKGROUND: The juvenile laryngeal papilloma is the most common benign neoplasm in children.
  • Often the entity shows an elongated recurrent course of disease with an expansion into the tracheo-bronchial system.
  • Sporadic malignant transformation in adults with a papilloma was reported after treatment with radiotherapy alone or in combination with the intake of additional toxins (e. g. nicotine).
  • Similar reports of a malignant transformation of juvenile papillomas without additional risk factors is very rarely reported.
  • The multiple laser surgical procedures and a therapy with interferon resulted in a short-term remissions.
  • Seven months after the first diagnosis of the papilloma a regional metastatic squamous cell carcinoma was found.
  • In spite of combined radiotherapy and chemotherapy the boy died 11 months later.
  • CONCLUSIONS: The spontaneous malignant transformation of a juvenile papilloma in a squamous cell carcinoma is extremely rare.
  • The surgical intervention as well the radiotherapy and chemotherapy using interferon was unsuccessful due to the high grade of malignancy.
  • In view of the very short time interval between first diagnosis of juvenile papilloma and the subsequent malignant transformation, one must consider either the potential presence of a very aggressive form of papilloma or alternative two coincident independent diseases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Laryngeal Neoplasms / pathology. Papilloma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Remission Induction. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080063.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


25. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a 68-year-old man who presented with a neck mass in the posterior triangle.
  • Fine-needle aspiration biopsy (FNAB) identified the mass as a malignant melanoma.
  • Postoperatively, he declined to undergo radio- and chemotherapy.
  • Eighteen months later, he returned with a diffusely enlarged thyroid.
  • He developed ventilator-dependent respiratory failure and required a subtotal thyroidectomy for the placement of a tracheostomy tube.
  • Patients who present with a thyroid nodule and who have a history of malignancy present a diagnostic dilemma: Is the nodule benign, a new primary, or a distant metastasis?
  • The findings of this case and a review of the literature strengthen the argument that any patient with a thyroid mass and a history of malignancy should be considered to have a metastasis until proven otherwise.
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


26. Vennarecci G, Ettorre GM, Giovannelli L, Del Nonno F, Perracchio L, Visca P, Corazza V, Vidiri A, Visco G, Santoro E: Solitary fibrous tumor of the liver. J Hepatobiliary Pancreat Surg; 2005;12(4):341-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the liver.
  • We report a new case of benign solitary fibrous tumor (SFT) of the liver.
  • Ultrasonography and computed tomography showed a large tumor, 20 cm in diameter, in the right lobe of the liver.
  • The tumor measured 30 x 28 x 14 cm and weighed 4725 g.
  • Microscopic evaluation showed a benign SFT of the liver with tumor cells typically positive for vimentin and CD34.
  • This is a rare neoplasm of mesenchymal origin that occasionally involves the liver in adult patients.
  • Most SFTs are benign, but some may have malignant histological features and recur locally or metastasize.
  • Because of their rarity, overall experience has not been significant and little has been published concerning this tumor, Including the present one, 28 cases have been reported in the English literature.
  • Surgery is the mainstay of treatment.
  • As SFT of the liver is often a benign neoplasm, chemotherapy or radiotherapy should not be necessary, and should be reserved for when resection is incomplete and/or histological examination reveals features of malignancy.
  • Surgeons must be aware of SFT of the liver, and this neoplasm should be included in the differential diagnosis of a single large hepatic mass.
  • [MeSH-major] Liver Neoplasms / pathology. Neoplasms, Fibrous Tissue / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16133706.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Yel L, Liao O, Lin F, Gupta S: Severe T- and B-cell immune deficiency associated with malignant thymoma. Ann Allergy Asthma Immunol; 2003 Nov;91(5):501-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Immunodeficiency with thymoma syndrome is a rare disorder that generally occurs after the fourth decade of life.
  • Typically, thymic tumors are benign, and gradually developing immunodeficiency consists of hypogammaglobulinemia with low B-cell counts and an inverted CD4+/CD8+ T-cell ratio due to excessive CD8+ T cells.
  • OBJECTIVE: To report the case of a 32-year-old, white man with an invasive malignant thymoma and profound combined T- and B-cell immunodeficiency associated with a normal CD4+/CD8+ T-cell ratio, absence of circulating B cells, and infection with an unusual organism.
  • METHODS: The patient presented with a superior vena cava syndrome caused by a malignant thymoma.
  • During chemotherapy and radiotherapy, he experienced recurrent episodes of pulmonary infections due to Haemophilus influenza and Serratia marcescens and persistent oral thrush.
  • RESULTS: Sixteen months after the diagnosis of thymoma, the immunological evaluation revealed profound lymphopenia, eosinopenia, very low counts of both CD4+ T cells and CD8+ T cells, and a normal CD4+/CD8+ ratio with negative delayed-type hypersensitivity skin test results.
  • Hypogammaglobulinemia and absent specific antibody responses were associated with a lack of peripheral blood CD19+ B cells.
  • Despite treatment with intravenous immunoglobulin, the patient died of respiratory insufficiency and sepsis secondary to a chronic pulmonary infection.
  • Comprehensive immunological evaluation should be performed when thymoma is diagnosed to initiate an early and effective treatment to prevent life-threatening complications.
  • [MeSH-major] Agammaglobulinemia / complications. B-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Immunologic Deficiency Syndromes / complications. Thymoma / complications. Thymus Neoplasms / complications
  • [MeSH-minor] Adult. Antibody Formation / immunology. Antibody Specificity / immunology. CD4-CD8 Ratio. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Lymphocyte Count. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Serratia Infections / diagnosis. Serratia Infections / immunology. Serratia Infections / microbiology. Serratia marcescens / immunology. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14692437.001).
  • [ISSN] 1081-1206
  • [Journal-full-title] Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • [ISO-abbreviation] Ann. Allergy Asthma Immunol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


28. Armbruster C: Novel treatments for recurrent respiratory papillomatosis. Expert Opin Investig Drugs; 2002 Aug;11(8):1139-48
Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel treatments for recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis is a rare but often severe disease.
  • Although benign in histology, epithelial proliferations may result in progressive hoarseness, stridor, obstruction of the airway and respiratory distress.
  • The current standard of care is surgical therapy with a goal of complete removal or debulking of papillomas and preservation of normal structures.
  • Frequent recurrences and the need for repeated surgical interventions make this treatment a frustrating experience for both the patient and the physician.
  • Many adjuvant therapies have been investigated but no single treatment modality proved to be effective in eradicating recurrent respiratory papillomatosis.
  • This review focuses on the current status of recurrent respiratory papillomatosis and on future directions of prevention and therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Neoplasm Recurrence, Local / prevention & control. Papilloma / drug therapy. Papillomaviridae / drug effects. Respiratory Tract Neoplasms / drug therapy
  • [MeSH-minor] Humans. Laser Therapy. Papillomavirus Infections / drug therapy. Papillomavirus Infections / surgery. Papillomavirus Infections / virology. Tumor Virus Infections / drug therapy. Tumor Virus Infections / surgery. Tumor Virus Infections / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12150707.001).
  • [ISSN] 1354-3784
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 85
  •  go-up   go-down


29. Morikawa M, Demura Y, Mizuno S, Ameshima S, Ishizaki T, Okazawa H: FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med; 2008 May;22(4):335-8
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG positron emission tomography imaging of drug-induced pneumonitis.
  • Several studies have reported the findings of fluorine-18-labeled fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) in benign lung disease with diffuse pulmonary injury; however, the characteristics and effectiveness of FDG-PET imaging for interstitial pneumonitis have not been substantiated.
  • We report two cases of drug-induced pneumonitis in two patients treated for breast cancer who were diagnosed by FDG-PET examination.
  • Both the cases showed diffuse interstitial infiltration in the bilateral lungs on computed tomography, but the degree of FDG accumulation was different.
  • It is probable that the degree of FDG accumulation reflected the activity of the drug-induced pneumonitis.
  • [MeSH-minor] Aged. Anxiety Disorders / drug therapy. Anxiety Disorders / etiology. Brain Neoplasms / complications. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Dibenzothiazepines / adverse effects. Dibenzothiazepines / therapeutic use. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / adverse effects. Paclitaxel / therapeutic use. Positron-Emission Tomography. Quetiapine Fumarate. Sensitivity and Specificity. Tomography, X-Ray Computed. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535887.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dibenzothiazepines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 2S3PL1B6UJ / Quetiapine Fumarate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


30. Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJ: Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol; 2005 Nov;114(11):836-9
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis.
  • Recurrent respiratory papillomatosis (RRP) is characterized by benign wartlike growths in the larynx with occasional spread to the lungs.
  • A broad range of therapeutic measures have been used to treat RRP; the primary treatment is laser vaporization of the lesions.
  • Recurrences of the disease are common, and alternate methods of treatment are being used to prevent recurrence, including cidofovir.
  • Cidofovir is a cytosine nucleotide analog with antiviral properties that is approved by the US Food and Drug Administration for treatment of cytomegalovirus retinitis and is currently being used off-label for RRP.
  • Cidofovir has gained initial success in slowing the rate of disease recurrence when used at the time of surgery.
  • We report here a 28-year-old woman who was treated with intralesional cidofovir at the time of surgery over the span of 27 months.
  • The initial pathology results demonstrated benign disease with progression to severe dysplasia during the treatment time.
  • [MeSH-major] Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / pathology. Papilloma / drug therapy. Papilloma / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Cytosine / administration & dosage. Cytosine / analogs & derivatives. Disease Progression. Female. Humans. Injections, Intralesional. Neoplasm Recurrence, Local. Organophosphonates / administration & dosage

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Otol Rhinol Laryngol. 2005 Nov;114(11):834-5 [16358602.001]
  • (PMID = 16358603.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


31. Wang H, Wan YX, Zhang QK: [Significance and expression of insulin-like growth factor 1 and IGF binding protein 3 in serum of patients with lung cancer]. Ai Zheng; 2004 Jun;23(6):710-4
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & OBJECTIVE: Insulin-like growth factors (IGFs) can strongly stimulate the proliferation of a variety of cancer cells, including lung cancer cells.
  • METHODS: Seventy-eight cases with lung cancer (A group), 35 with benign pulmonary disease (B group), and 14 healthy controls (C group) were included in this study.
  • For the cases with lung cancer in pre-chemotherapy, the serum IGF(1) level was higher in patients with lymphoid node metastasis, and IGFBP(3) level of them was significantly lower than those without metastasis(P< 0.05).
  • Fourteen post-chemotherapy patients showed a lower IGF(1) [(480.29+/-117.93)microg/L] than those in pre-chemotherapy[(661.76+/-153.54)microg/L](P< 0.05),whereas IGFBP(3) level was in inverse to IGF(1).
  • [MeSH-major] Insulin-Like Growth Factor Binding Protein 3 / blood. Insulin-Like Growth Factor I / metabolism. Lung Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Female. Humans. Lung Diseases / blood. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191678.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


32. Spiro SG, Porter JC: Lung cancer--where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med; 2002 Nov 1;166(9):1166-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.
  • Lung cancer remains the commonest cause of cancer death in both men and women in the developed world, although mortality rates for men are dropping.
  • Spiral computed tomography (CT) of the chest in middle-aged, smoking subjects may identify two to four times more lung cancers than a chest X-ray, with more than 70% of tumors being Stage I.
  • The incidence of benign nodules is high, making interpretation difficult.
  • Preoperative staging has relied on CT scans, but positron emission tomography scanning has greater sensitivity, specificity, and accuracy than CT and is recommended as the final confirmatory investigation when the CT shows resectable disease.
  • In locally advanced non-small cell lung cancer, there is a small advantage for the addition of chemotherapy to radiotherapy, but no advantage for postoperative radiotherapy.
  • Chemotherapy gives no benefit when given as neoadjuvant or adjuvant treatment around surgery.
  • Survival with small cell lung cancer has shown little increase over the last 15 years despite multiple attempts to manipulate the timing, dose intensity of chemotherapy, and the potential of radiotherapy.
  • Novel therapies are urgently needed for all cell types of lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / drug therapy. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Medical Oncology / organization & administration. Neoplasm Staging / trends
  • [MeSH-minor] Female. Humans. Male. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12403687.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 324
  •  go-up   go-down


33. Nowaczewska K, Wójtowicz P, Kukwa A, Ratajczak J, Tulibacki M: [Respiratory papillomatosis--new methods of treatment]. Otolaryngol Pol; 2010 Jan-Feb;64(1):31-6
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Respiratory papillomatosis--new methods of treatment].
  • BACKGROUND: Respiratory papillomatosis is caused by HPV.
  • The disease is benign but recurrent.
  • The aim of this study was to estimate new methods of treatment respiratory papillomatosis based on intralesional injection of cidofovir into sites where papillomas had just been excised.
  • The treatment was based on surgical excision of papilloma and after it intralesional injection of cidofovir in after 4-5 weeks.
  • 41 patients had 4 times intralesional injection of cidofovir.
  • We observed that this treatment caused long lasting remission of papilloma recurrence.
  • [MeSH-major] Antiviral Agents / administration & dosage. Cytosine / analogs & derivatives. Laryngeal Neoplasms / drug therapy. Organophosphonates / administration & dosage. Papilloma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Drug Administration Schedule. Female. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Poland. Remission Induction. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20476590.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down






Advertisement